Treating violence as a public health problem.

1 Giddens A. Modernity and self-identity. Cambridge: Polity, 1991. 2 Dixon-Woods M, Baum M, Kurinczuk JJ. Screening for breast cancer with mammography Lancet 358:2166-7. 3 Ciatto S, Zappa R, Bonardi G, Gervasi G. Prostate cancer screening: the problem of overdiagnosis and lessons to be learned from breast screening. Eur J Cancer 2000;36:1347-50. 4 NHS Cancer Screening Programmes. The prostate cancer risk management programme. www.cancerscreening.nhs.uk/prostate/ index.html (accessed 26 Sep 2002). 5 Lu-Yao G, Albertson PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. A natural experiment examining the impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from the Seattle area and Connecticut. BMJ 2002;325:740-3. 6 Chapple A, Ziebland S, Shepperd S, Miller R, Herxheimer A, McPherson A. Why men with prostate cancer want wider access to prostate specific antigen (PSA) testing: qualitative study. BMJ 2002;325:737-9. 7 Donovan J, Mills N, Brindle L, Frankel S, Smith M, Jacoby A, et al. Improving the design and conduct of randomised trials by embedding them in qualitative research: the ProtecT study. BMJ 2002;325:766-70. 8 Girgis ST, Thomson C, Ward J. “The courts expect the impossible”: medico-legal issues as perceived by New South Wales general practitioners. J Law Med 2000;7:273-80. 9 Thornton H. Consequences of screening. Lancet 2000;356:1033. 10 Cochrane AL, Holland WW. Validation of screening procedures. Br Med Bull 1971;27:3-8. 11 Thornton H, Dixon-Woods M. Recruitment of women into trials. Lancet 2002;359:164-5. 12 Ward J, Girgis S. GPs’ estimates of men’s risk of prostate cancer and screening expectations. Austr N Z J Public Health 1999;23:219-20.